Hydro Power Is Most Effective Renewable Energy

Source: Click Green (5/26/11)

"Hydro schemes show best renewable efficiency in study."

Click Green
Hydro power

The Renewable Energy Foundation (REF) has announced the publication of its online searchable database of the small renewable energy generators subsidized under the Feed-in-Tariff (FiT) scheme.

Analysis of that data, and related Ofgem renewables data, show that small hydro is the best performer in the FiTs stable.

The database is based on material released quarterly by Ofgem following a Freedom of Information request by REF in 2010.

REF is also publishing an information note on the performance of the FiT scheme in its first year, the key findings of which are:

Growth in small solar photovoltaic (PV) projects accounts for nearly all the increase in installed renewable microgeneration.
The geographic location of favored areas for solar PV includes significant concentrations in Sheffield, Barnsley and Rotherham, suggesting that factors other than resource availability are driving adoption.
Historical average annual load factors for all microgenerators suggest that small hydro could deliver more energy than micro PV or wind, with the better hydro sites able to command good returns for investors.
The FiTS generators installed at 31 March 2011 would generate approximately 140 gigawatt-hour (GWh) per annum, which is 0.1% of the 119 TWh required to meet the EU 2020 target for 15% of renewable energy.
Government expects that the FiT scheme will deliver 6 TWh of renewable electricity in 2020. This would require current output to increase more than 40 times in nine years.

Dr. Lee Moroney, Director of Planning for REF said, "Our data analysis shows that small hydro is producing respectable volumes of renewable electricity and satisfactory returns on investment, yet it has been overlooked in comparison with domestic solar PV. Given the scale of the targets before us, adoption of a broader range of microgeneration would be desirable."

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.